camptothecin/podophyllotoxin (NEV-801) / Neovia Oncology - LARVOL DELTA

A Phase 1, Open-Label, Dose-Escalation Study of NEV801, Administered to Patients With Advanced Cancers (clinicaltrials.gov) - P1; N=78; Recruiting; Sponsor: Neovia Oncology Ltd.; Trial completion date: Dec 2020 ➔ Dec 2021; Trial primary completion date: Dec 2020 ➔ Dec 2021

Clinical • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

A Phase 1, Open-Label, Dose-Escalation Study of NEV801, Administered to Patients With Advanced Cancers (clinicaltrials.gov) - P1; N=78; Recruiting; Sponsor: Neovia Oncology Ltd.; Trial completion date: Dec 2019 ➔ Dec 2020; Trial primary completion date: Dec 2019 ➔ Dec 2020

Clinical • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

A Phase 1, Open-Label, Dose-Escalation Study of NEV801, Administered to Patients With Advanced Cancers (clinicaltrials.gov) - P1; N=78; Recruiting; Sponsor: Neovia Oncology Ltd.; Not yet recruiting ➔ Recruiting; Initiation date: Jul 2016 ➔ Dec 2016

Enrollment open • Trial initiation date • Biosimilar • Oncology

A Phase 1, Open-Label, Dose-Escalation Study of NEV801, Administered to Patients With Advanced Cancers (clinicaltrials.gov) - P1; N=78; Recruiting; Sponsor: Neovia Oncology Ltd.; Trial completion date: Jul 2018 ➔ Dec 2019; Trial primary completion date: Jul 2018 ➔ Dec 2019

Clinical • Trial completion date • Trial primary completion date